Derm-Biome Pharmaceuticals announced positive preclinical results for its topical drug DB-007-5 in treating atopic dermatitis (AD). The drug significantly reduced inflammation and outperformed the current leading AD treatment, Opzelura, in reducing itch, a key symptom of AD. DB-007-5 also demonstrated a favorable safety profile in previous studies.
This development holds substantial promise for patients suffering from AD, a chronic inflammatory skin disease affecting a significant portion of the population, particularly children. Current treatment options often provide inadequate relief or are associated with side effects, highlighting a need for safer and more effective therapies, especially for mild to moderate cases. The positive results for DB-007-5 suggest it could address this unmet need, potentially offering a new first-line treatment option and improving the quality of life for millions.
DB-007-5 at a 0.75% concentration was more effective at reducing itch than Opzelura (1.5% ruxolitinib cream). Prior studies also showed DB-007-5’s superior efficacy compared to Pfizer’s Eucrisa. These findings position DB-007-5 as a potential best-in-class topical treatment for AD.
The successful preclinical results for DB-007-5 pave the way for further clinical development. If subsequent trials confirm these positive findings, Derm-Biome could significantly impact the AD treatment landscape, offering a new, effective, and safe topical option for patients. This could also lead to substantial market share capture within the growing AD therapeutics market.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
